Anticholinergics boost the pathological process of neurodegeneration with increased inflammation in a tauopathy mouse model

Neurobiology of Disease

Volumn 45, Issue 1, 2012, Pages 329-336

  Yoshiyama, Yasumasa ^a   Kojima, Ayako ^a   Itoh, Kimiko ^a   Uchiyama, Tomoyuki ^b   Arai, Kimihito ^a  

^a SAKURA NATIONAL HOSPITAL   (Japan)

^b CHIBA UNIVERSITY   (Japan)

Author keywords

Anticholinergics; Inflammation; Neurodegeneration; Tau

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; PROPIVERINE; TAU PROTEIN; TRIHEXYPHENIDYL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN REGION; CELL ACTIVATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; HIPPOCAMPUS; IMMUNOHISTOCHEMISTRY; MICROGLIA; MOUSE; NERVE CELL; NERVE DEGENERATION; NEUROTRANSMISSION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TAUOPATHY;

ANIMALS; BENZILATES; CHOLINERGIC ANTAGONISTS; DISEASE MODELS, ANIMAL; HIPPOCAMPUS; INFLAMMATION; MICE; NERVE DEGENERATION; NEURONS; TAU PROTEINS; TAUOPATHIES; TRIHEXYPHENIDYL;

EID: 81955160720     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2011.08.017     Document Type: Article

References (30)

1. Ancelin M.L., et al. Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: longitudinal cohort study. BMJ 2006, 332:455-459.
2. Binder L.I., et al. The distribution of tau in the mammalian central nervous system. J. Cell Biol. 1985, 101:1371-1378.
3. Bonotis K., et al. Systemic immune aberrations in Alzheimer's disease patients. J. Neuroimmunol. 2008, 193:183-187.
4. Borchelt D.R., et al. A vector for expressing foreign genes in the brains and hearts of transgenic mice. Genet. Anal. 1996, 13:159-163.
5. Campbell J.A., et al. Postnatal hepatic fatty acid oxidative capacity of preterm pigs receiving TPN does not differ from that of term pigs and is not affected by supplemental arachidonic and docosahexaenoic acids. J. Nutr. 2010, 140:752-759.
6. Campbell N.L., et al. Use of anticholinergics and the risk of cognitive impairment in an African American population. Neurology 2010, 75:152-159.
7. Carriere I., et al. Drugs with anticholinergic properties, cognitive decline, and dementia in an elderly general population: the 3-city study. Arch. Intern. Med. 2009, 169:1317-1324.
8. De Simone R., et al. Activation of alpha7 nicotinic acetylcholine receptor by nicotine selectively up-regulates cyclooxygenase-2 and prostaglandin E2 in rat microglial cultures. J. Neuroinflammation 2005, 2:4.
9. Heneka M.T., O'Banion M.K. Inflammatory processes in Alzheimer's disease. J. Neuroimmunol. 2007, 184:69-91.
10. Holmes C., et al. Systemic inflammation and disease progression in Alzheimer disease. Neurology 2009, 73:768-774.
11. Ishihara T., et al. Age-dependent emergence and progression of a tauopathy in transgenic mice overexpressing the shortest human tau isoform. Neuron 1999, 24:751-762.
12. Jessen F., et al. Anticholinergic drug use and risk for dementia: target for dementia prevention. Eur. Arch. Psychiatry Clin. Neurosci. 2010, 260(Suppl 2):S111-S115.
13. Kobayashi F., et al. Pharmacological effects of imidafenacin (KRP-197/ONO-8025), a new bladder selective anti-cholinergic agent, in rats. Comparison of effects on urinary bladder capacity and contraction, salivary secretion and performance in the Morris water maze task. Arzneimittelforschung 2007, 57:147-154.
14. Lee K.S., et al. Peripheral cytokines and chemokines in Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 2009, 28:281-287.
15. Lee S.T., et al. Cholinergic anti-inflammatory pathway in intracerebral hemorrhage. Brain Res. 2010, 1309:164-171.
16. Moore A.R., O'Keeffe S.T. Drug-induced cognitive impairment in the elderly. Drugs Aging 1999, 15:15-28.
17. Mulsant B.H., et al. Serum anticholinergic activity in a community-based sample of older adults: relationship with cognitive performance. Arch. Gen. Psychiatry 2003, 60:198-203.
18. Oka T., et al. Effects of antimuscarinic drugs on both urinary frequency and cognitive impairment in conscious, nonrestrained rats. Jpn. J. Pharmacol. 2001, 87:27-33.
19. Pavlov V.A., et al. Brain acetylcholinesterase activity controls systemic cytokine levels through the cholinergic anti-inflammatory pathway. Brain Behav. Immun. 2009, 23:41-45.
20. Perry E.K., et al. Increased Alzheimer pathology in Parkinson's disease related to antimuscarinic drugs. Ann. Neurol. 2003, 54:235-238.
21. Pollak Y., et al. Acetylcholinesterase inhibitors reduce brain and blood interleukin-1beta production. Ann. Neurol. 2005, 57:741-745.
22. Suzuki M., et al. Effect of antimuscarinic drugs used for overactive bladder on learning in a rat passive avoidance response test. Eur. J. Pharmacol. 2007, 557:154-158.
23. Tan Z.S., et al. Inflammatory markers and the risk of Alzheimer disease: the Framingham Study. Neurology 2007, 68:1902-1908.
24. Tune L., et al. Anticholinergic effects of drugs commonly prescribed for the elderly: potential means for assessing risk of delirium. Am. J. Psychiatry 1992, 149:1393-1394.
25. Tyagi E., et al. Effect of anti-dementia drugs on LPS induced neuroinflammation in mice. Life Sci. 2007, 80:1977-1983.
26. Wang H., et al. Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature 2003, 421:384-388.
27. Yaffe K., et al. The metabolic syndrome, inflammation, and risk of cognitive decline. JAMA 2004, 292:2237-2242.
28. Yoshiyama Y., et al. Selective distribution of matrix metalloproteinase-3 (MMP-3) in Alzheimer's disease brain. Acta Neuropathol. (Berl) 2000, 99:91-95.
29. Yoshiyama Y., et al. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 2007, 53:337-351.
30. Yoshiyama Y., et al. Anti-inflammatory action of donepezil ameliorates tau pathology, synaptic loss, and neurodegeneration in a tauopathy mouse model. J. Alzheimers Dis. 2010, 22:295-306.